Register
Medicines reference
Product

Amodip

Amlodipine · Ceva Sante Animale

1 form: chewable tablet. No registration in force in Georgia.

Forms and doses0 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Enter weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
1.25 mg chewable tablets for cats, Chewable tablet · Cat 2.5–5 kg Cat 2.5–5 kg 1/2 tablet
Initial labelled dose 0.125-0.25 mg/kg once daily. Reassess after 14 days; only if SBP remains above 150 mmHg or has fallen by less than 15%, double the dose or increase up to 0.5 mg/kg once daily. Safety and dose accuracy are not established below 2.5 kg. Return a used half to the blister and use within 24 hours.
· once daily (starting dose)
once daily (starting dose) Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
1.25 mg chewable tablets for cats, Chewable tablet · Cat 5–10 kg Cat 5–10 kg 1 tablet
Initial labelled dose 0.125-0.25 mg/kg once daily. Reassess after 14 days; only if SBP remains above 150 mmHg or has fallen by less than 15%, double the dose or increase up to 0.5 mg/kg once daily. Safety and dose accuracy are not established below 2.5 kg. Return a used half to the blister and use within 24 hours.
· once daily (starting dose)
once daily (starting dose) Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
1.25 mg chewable tablets for cats, Chewable tablet · Cat over 10 kg Cat over 10 kg 2 tablets
Initial labelled dose 0.125-0.25 mg/kg once daily. Reassess after 14 days; only if SBP remains above 150 mmHg or has fallen by less than 15%, double the dose or increase up to 0.5 mg/kg once daily. Safety and dose accuracy are not established below 2.5 kg. Return a used half to the blister and use within 24 hours.
· once daily (starting dose)
once daily (starting dose) Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Amodip 1.25 mg chewable tablets for cats, Chewable tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.9/10
Very good
vetman assessment

Amodip

1.25 mg chewable tablets for cats
Assessed clinical scopeCat · Control of confirmed persistent systemic hypertension in cats, with investigation and treatment of the underlying disease and target-organ damage · By mouth
Care settingVeterinarian-directed chronic home treatment after repeat blood-pressure confirmation, with a 14-day response/titration review and serial BP, clinical, renal, hepatic and electrolyte monitoring
vetman score 8.9/10 Very good
Evidence confidence: High Georgia: No · Verified on 22 Oct 2026

A very good, first-line, label-concordant feline antihypertensive with unusually strong exact-product evidence and once-daily practicality. Confirm persistent hypertension rather than treating one stressed reading, assess target-organ damage and underlying disease, titrate to measured response and retain long-term BP, oral, electrolyte and clinical monitoring.

Regulatory and scientific credibility9.5/10

The exact feline product has current transparent EU/EEA, GB and US veterinary authorisations, a current label, an FDA-reviewed dossier, a masked controlled field study and target-animal safety data. Professional consensus independently supports the same first-line role; Georgia lacks exact registration and exact-form pivotal work is partly sponsor-linked.

Clinical efficacy9.0/10

In a 77-cat randomised placebo-controlled trial, about 64% responded to Amodip versus 18% to control, with substantial SBP reduction; smaller blinded and long-term cohorts and ACVIM/ISFM guidance are consistent. Fundic lesions often improve, but some cats need titration or remain nonresponders and survival, renal-preservation and reversal-of-blindness benefits are not proven.

Safety and tolerability8.0/10

Correct label use has a well-characterised and generally manageable safety profile. Vomiting, anorexia, diarrhoea, lethargy/dehydration, gingival hyperplasia, electrolyte decreases and hypotension remain relevant; severe hepatic disease, cardiogenic shock and severe aortic stenosis are contraindications, and safety is unresolved below 2.5 kg, in heart failure and during pregnancy/lactation.

Clinical practicality9.0/10

Once-daily oral use, feline-flavoured scored tablets, exact half-tablet bands and direct-or-small-food administration are highly workable. Most field-study cats took the tablet directly or with food, but some required pilling; confirmation, 14-day titration review, serial BP checks, 24-hour half-tablet life and the under-2.5-kg dosing gap remain real burdens.

Full-course cost-effectiveness-

No verified current Georgian exact-pack price, dependable availability or patient-adjusted chronic treatment cost was found; foreign prices and human amlodipine substitutes were not used.

Important safety and use flags

  • Do not treat a single high in-clinic reading as persistent hypertension. Unless acute ocular or neurologic target-organ damage makes delay unsafe, use a standard low-stress technique and confirm elevated systolic pressure on different days before starting chronic treatment.
  • Identify and treat contributing disease such as CKD, hyperthyroidism, diabetes or hyperaldosteronism, and examine the fundus, neurologic status, heart and kidneys for target-organ damage. Amodip controls pressure; it does not replace disease-specific care.
  • Use the exact starting table: 2.5-5.0 kg half a tablet, 5.1-10.0 kg one tablet, and 10.1 kg or more two tablets once daily. This presentation cannot accurately dose cats under 2.5 kg. Do not start at the 0.5 mg/kg ceiling.
  • Recheck systolic pressure after 14 days. Double or increase up to 0.5 mg/kg once daily only if SBP remains above 150 mmHg or has fallen by less than 15%; thereafter monitor routinely, commonly every 6-8 weeks, and avoid excessive hypotension.
  • Monitor appetite, vomiting, diarrhoea, hydration, lethargy, weight, oral tissues, potassium and chloride. Gingival hyperplasia is dose- and time-related; clinically important hyporexia, dehydration, weakness, hypotension or oral disease requires reassessment rather than automatic continuation.
  • Do not use in cardiogenic shock, severe aortic stenosis, severe hepatic failure or amlodipine/excipient hypersensitivity. In lesser hepatic disease use a documented benefit-risk decision because amlodipine is extensively metabolised by the liver.
  • Other antihypertensives, diuretics, RAAS inhibitors, vasodilators and alpha-2 agonists can add hypotension. Beta-blockers, cardioselective calcium-channel blockers and azole antifungals can also reduce cardiac rate or contractility; review hydration, BP and ventricular function before combining.
  • Safety is not established in cardiac failure, pregnancy or lactation. Use in these groups only after an explicit veterinary benefit-risk assessment; do not infer reproductive safety from rodent data or routine safety in stable hypertensive geriatric cats.
  • Give directly or with only a small amount of food and confirm the full dose is swallowed. Return the unused half to its blister, use it within 24 hours and keep the flavoured tablets away from animals and children; accidental ingestion can cause clinically important hypotension.
  • Acute blindness, retinal detachment/haemorrhage or neurologic signs with severe hypertension is urgent target-organ damage. Prompt BP control may reattach retina or improve lesions, but established severe retinal degeneration and vision loss can remain irreversible.
Assessment sources
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Amlodipine1.25 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
EU Yes, veterinary
№ FR/V/0413/001
Verified on: 22 Oct 2026
UK Yes, veterinary
№ Vm 14966/5022
Verified on: 22 Oct 2026
US Yes, veterinary
№ NADA 141-613
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Labelled initial dose for confirmed feline systemic hypertension: 0.125-0.25 mg amlodipine/kg PO once daily. Starting table: 2.5-5.0 kg, half a tablet; 5.1-10.0 kg, one tablet; 10.1 kg or more, two tablets. Recheck at 14 days and only double or increase up to 0.5 mg/kg once daily if SBP remains above 150 mmHg or has fallen by less than 15%. Confirm stable hypertension, investigate/treat the cause and monitor BP, renal/liver values and electrolytes.
DoseSpeciesWeightRouteFrequencySource
1/2 tablet
Initial labelled dose 0.125-0.25 mg/kg once daily. Reassess after 14 days; only if SBP remains above 150 mmHg or has fallen by less than 15%, double the dose or increase up to 0.5 mg/kg once daily. Safety and dose accuracy are not established below 2.5 kg. Return a used half to the blister and use within 24 hours.
Cat 2.5–5 kg By mouth once daily (starting dose)
Amodip current SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Amodip 1.25 mg chewable tablets for cats - current product information, revised September 2025
UK Veterinary Medicines Directorate, 2025
1 tablet
Initial labelled dose 0.125-0.25 mg/kg once daily. Reassess after 14 days; only if SBP remains above 150 mmHg or has fallen by less than 15%, double the dose or increase up to 0.5 mg/kg once daily. Safety and dose accuracy are not established below 2.5 kg. Return a used half to the blister and use within 24 hours.
Cat 5–10 kg By mouth once daily (starting dose)
Amodip current SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Amodip 1.25 mg chewable tablets for cats - current product information, revised September 2025
UK Veterinary Medicines Directorate, 2025
2 tablets
Initial labelled dose 0.125-0.25 mg/kg once daily. Reassess after 14 days; only if SBP remains above 150 mmHg or has fallen by less than 15%, double the dose or increase up to 0.5 mg/kg once daily. Safety and dose accuracy are not established below 2.5 kg. Return a used half to the blister and use within 24 hours.
Cat over 10 kg By mouth once daily (starting dose)
Amodip current SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Amodip 1.25 mg chewable tablets for cats - current product information, revised September 2025
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use in the case of cardiogenic shock and severe aortic stenosis.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of severe hepatic failure. Special caution is required in patients with hepatic disease as amlodipine is highly metabolised by the liver. As no studies have been conducted in animals with liver disease, use of the product in these animals should be based on a benefit-risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning
    Safety has not been tested in cats with cardiac failure. Use in these cases should be based on a benefit risk assessment by the veterinarian.
    Sources: VMD SPC · VMD
  • Warning
    When amlodipine is given together with other drugs that lower blood pressure, measure blood pressure before starting and make sure the cat is adequately hydrated. Do not start a calcium channel blocker or a RAAS inhibitor in a dehydrated, unstable cat.
    Sources: VMD SPC · VMD · IRIS
  • Warning
    The safety of amlodipine has not been established during pregnancy and lactation in cats.
    Sources: VMD SPC · VMD
  • Warning
    The safety of amlodipine has not been established during pregnancy and lactation in cats.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Amlodipine + Maropitant
    The veterinary medicinal product should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
    Recommendation: None
    Sources: VMD SPC · VMD
  • Minor warning Benazepril + Amlodipine
    Both drugs lower blood pressure, so hypotension is theoretically possible when they are combined. In hypertensive cats treated with amlodipine and benazepril together, however, no hypotension caused by the combination has been observed.
    Recommendation: This combination is not prohibited and may be used when one agent does not adequately control blood pressure. Measure blood pressure before treatment and ensure adequate hydration. Target systolic pressure is below 160 mmHg; below 120 mmHg or weakness/tachycardia indicates hypotension.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Telmisartan + Amlodipine
    During concomitant therapy with amlodipine at the recommended dose, no clinical evidence of hypotension was observed.
    Recommendation: Combine amlodipine and telmisartan only when either drug alone does not control blood pressure adequately. Measure blood pressure before treatment, correct dehydration, and recheck regularly after stabilisation.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Furosemide + Amlodipine
    Concomitant use of amlodipine with other agents that may reduce blood pressure may cause hypotension. These agents include: diuretics, beta-blockers, other calcium channel blockers, inhibitors of the renin angiotensin aldosterone system... and alpha-2 agonists. may sometimes result in a decrease in serum potassium and chloride levels
    Recommendation: Before combining amlodipine with these agents, measure blood pressure and ensure that the cat is adequately hydrated. Monitor electrolytes and hydration during treatment.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Pimobendan + Amlodipine
    Beta-adrenergic blockers such as propranolol or atenolol and calcium-channel blockers such as verapamil or diltiazem can reduce the positive inotropic effect of pimobendan.
    Recommendation: Monitor clinical response.
    Sources: Vetmedin SPC

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.